Cure Genetics Awarded Third Place in the 2024 Biomedical Pitch Competition


Cure Genetics is honored to announce that it has awarded the third-place prize at the recently concluded 2024 Biomedical Pitch Competition finals. The company stood out among nearly a hundred international projects, winning third place. The finals were held at the Simcere Boston Innovation Center in Cambridge, gathering elites from the global biopharmaceutical field and attracting over 17,000 active international viewers through a live webcast.

This competition, co-organized by the Hong Kong Science and Technology Parks Corporation (HKSTP) and the Boston Chinese Investment Club (BCIC), showcased a multitude of high-quality projects and well-known international investment institutions. The competition featured early to mid-stage projects in various sectors, including pharmaceuticals, medical devices, diagnostic tools, and AI in pharmaceuticals. Non-Chinese teams made up more than thirty percent of the contestants, reflecting a high degree of international participation. After a rigorous selection process, 20 teams were chosen from the initial 90 entrants to compete in the semifinals, with 14 elite teams making it to the final stage on April 27.

At the highly competitive finals, Dr. Shawn He, Chief Scientific Officer of Cure Genetics, comprehensively presented the company's pioneering cell therapy technology platform, AIMS CAR-NKT, and the innovative product pipeline incubated by the platform. With its technological innovation and breakthrough data shown in preclinical and clinical stages, Cure Genetics distinguished itself and received high praise from industry experts and international investors, including HKSTP, Roche Accelerator, Kendall Capital Partners, PagodaTree Partners, and LB Ventures.

This award not only showcases Cure Genetics' expertise and innovative spirit in the field of cell therapy but also provides valuable opportunities for the company's future international development and cooperation. We look forward to using this opportunity to further strengthen cooperation with the global biopharmaceutical community. Through our international strategy and external licensing, we actively move forward with new drug research and commercialization, aiming to provide effective treatments for patients worldwide with unmet medical needs, and striving to become a benchmark in the field of cell and gene therapy.